-4%

est. 2Y upside i

HealthcareSeries A

Blood Test for Early Detection of Ovarian Cancer

Rank

#3040

Sector

Biotech

Est. Liquidity

~4Y

Data Quality

Data: Low

AOA Dx presents a high-risk opportunity for a job candidate: enterprise value is $40M (likely stale) against $40.7M in total funding, creating severe preference overhang that leaves common stock with little buffer.

Last updated: July 3, 2026

Bull (10%)+278%

Successful FDA clearance and positive pivotal trial data drive enterprise valuation to $200M by year 2. Common stock benefits from residual value after $40.7M liquidation preference, resulting in ~278% upside net of dilution.

Base (45%)+28%

Steady clinical progress leads to enterprise valuation of $100M. After satisfying preference, common stock sees ~28% upside net of dilution, but due to overhang the absolute return remains modest.

Bear (45%)-100%

Clinical setbacks or competitive pressure cause valuation to drop below $40.7M liquidation preference, rendering common stock worthless. Net of dilution, the employee's equity is fully wiped out.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

10175%

Total liquidation preference of $40.7M exceeds current valuation of $40M, meaning common stock is technically underwater at entry.

Dilution Risk

high

With $40.7M total funding and clinical-stage burn, a Series B round within 24 months is likely, potentially diluting common shareholders by 15-25%.

Secondary Liquidity

none

No secondary market exists for AOA Dx shares; employee equity is illiquid until an exit event (acquisition or IPO), which is unlikely within 2 years.

View all 4 open roles at AOA Dx →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on AOA Dx's data — designed to show you've done your homework.

  • 1

    “What are the key clinical milestones over the next 12-18 months that could materially de-risk the investment thesis?”

  • 2

    “How does AOA Dx's GlycoLocate platform compare to competitors' multi-omics approaches on cost, sensitivity, and regulatory pathway?”

  • 3

    “Given the preference overhang and likely need for further funding, how does the company plan to structure future rounds to minimize employee dilution?”

Community

Valuation Sentiment

Our model estimates -4% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.